Clinical Research Directory
Browse clinical research sites, groups, and studies.
Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients
Sponsor: Centre Hospitalier Universitaire de Nice
Summary
Type 2 diabetes currently affects around 4 million people in France, with the number of cases rising steadily. Complications of T2DM are essentially cardiovascular. In particular, T2DM is associated with calcification of peripheral vessel walls (mediacalcosis), responsible for increased vascular stiffness. This calcium deposition is known to be a cardiovascular risk factor, but the mechanism of its deposition in relation to diabetes is not clearly established. An important blood compound, inorganic pyrophosphate (PPi), which is the body's natural anti-calcifier is impacted in some way in T2DM. PPi is degraded by alkaline phosphatase (ALP), and is produced by an enzyme called ENPP1. ENPP1 activity is decreased and APL activity increased in insulin-resistant subjects, which could contribute to a decrease in tissue and circulating PPi, and thus favor a tissue pro-calcifying balance. We propose to test this hypothesis in a pilot study characterizing plasma PPi levels, in relation to ENPP1 activity, in type 2 diabetic patients. The aim of the study is also to determine if there is a link between blood PPi levels and the progression of calcifications in arteries.
Key Details
Gender
MALE
Age Range
40 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-06-18
Completion Date
2026-07-18
Last Updated
2025-07-10
Healthy Volunteers
No
Conditions
Interventions
Plasmatic PPi level
Plasmatic PPi level dosage at visit 1
Locations (1)
CHU de Nice
Nice, France, France